Drug Trial Radar · NCT04830813
Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Dec 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
184
Actual
Start
Mar 5, 2021
Primary completion
Apr 1, 2024
Study completion Apr 1, 2024
Sponsor
- Lead sponsor
- Chipscreen Biosciences, Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 5, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Chiauranib , which simultaneously targets against VEGFR/Aurora B/CSF-1R, several key kinases involved in tumor angiogenesis, tumor cell mitosis, and chronic inflammatory microenvironment.
Conditions
- Small Cell Lung Cancer
Interventions
ChiauranibDrug
Patients take Chiauranib capsules 50mg, orally once daily, 21 days as a cycle until objective disease progression.
PlaceboDrug
Participants received Chiauranib placebo capsule matching Chiauranib orally once daily until objective disease progression.
Primary outcomes
What the sponsor says the trial is designed to measure.
- PFSTime frame: From date of the first dose of study drug until the date of first documented progression or relapse or date of death from any cause, whichever came first, assessed up to 24 months
- OSTime frame: From date of the first dose of study drug until the date of death from any cause, assessed up to 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.